⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Metformin
Current understanding
Cheap, long-studied; TAME trial framing made it the poster child for aging-as-indication.
Evidence log
- 2026-11-13 — Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.: [animal-model] A preclinical study combining endometrial stromal cell experiments with aged-mouse experiments reported reduced cellular senescence, improved uterine histology and increased litter size with metformin, with functional involvement of TERT and AKT/mTOR signaling; it does not establish human reproductive-aging benefits or lifespan extension. [animal-model] (novelty: 3)
- 2026-11-11 — Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.: [human-rct — protocol only, no outcome results] HABIT-GEMs uses metformin XR as the active comparator in a multicentre, randomized, open-label trial testing henagliflozin’s non-inferiority for appendicular skeletal muscle mass preservation in adults aged 60–85 with newly diagnosed type 2 diabetes; comparator status does not establish metformin’s muscle-protective efficacy or resolve the page’s observational sarcopenia signal. [human-rct] (novelty: 3)
- 2026-11-04 — Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design.: [human-rct — trial design only, no outcome results] The multicenter phase III AMICO randomized trial is designed to test whether metformin 850 mg twice daily for 36 months slows lung function decline and reduces age-related comorbidities in COPD, without yet establishing either benefit. [human-rct] (novelty: 4)
- 2026-09-29 — Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies: cross-connection with ampk-activators: Metformin’s geroprotective hypothesis leans heavily on indirect AMPK activation; direct-activator lifespan extension in three species strengthens the pathway-level rationale without being metformin evidence. (novelty: 3)
- 2026-10-01 — Metformin in Elderly Patients With Type 2 Diabetes and Muscle Strength, Muscle Mass, and Physical Function: Positive or Negative Correlation?: Propensity-matched observational study in elderly T2D patients found long-term metformin use associated with higher prevalence of low grip strength, and — in those with poor glycemic control — worse skeletal muscle mass and gait speed; cautionary sarcopenia signal, not a causal trial. [human-observational] (novelty: 3)
- 2026-09-10 — Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.: Used as active comparator in an aged ApoE mouse cardiac-remodeling study of Mito-Esc; Mito-Esc effects on AMPK–SIRT1/p38 MAPK-driven hypertrophy, fibrosis, and senescence were reported comparable to metformin — no new metformin outcome data. [animal-model] (novelty: 3)
- 2026-09-11 — Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.: Mitochondrial homeostasis review of musculoskeletal disease positions metformin as a mechanism-matched intervention for AMPK/mitochondrial-dysfunction phenotypes across osteoporosis, osteoarthritis, and rheumatoid arthritis — narrative synthesis, no new MSK outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.: QSP simulation ranks metformin into the metabolic-optimal triple (with GLP-1 RA + SGLT2i) but NOT into the aging-optimal triple (where rapamycin replaces it), reinforcing the divergence between metabolic-endpoint and aging-endpoint predictions — model output only, not outcome evidence. [mechanism-plausible] (novelty: 3)
- 2026-08-03 — Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.: cross-connection with berberine: Review’s framing of berberine as the metabolic-regulation arm reinforces the long-standing ‘nature’s metformin’ analogy relevant to metformin’s mechanistic space. (novelty: 3)
Open questions
Related
Contributing findings
Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.
13-nov-2026
novelty 3
per-area 3
strengthens
Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.
11-nov-2026
novelty 3
per-area 3
strengthens
Is metformin use associated with cognitive, physical and cardiovascular outcomes in older adults with type 2 diabetes? A secondary analysis of the SCOPE multicentre prospective cohort study.
09-nov-2026
novelty 2
per-area 2
strengthens
Targeting Accelerated Aging in COPD: The AMICO (A Trial of Metformin In COpd) Trial Design.
04-nov-2026
novelty 4
per-area 4
strengthens
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026
novelty 3
per-area 2
mentions
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Direct Pharmacological Activation of AMPK Modestly Extends Life in Short-Lived Species
07-oct-2026
novelty 2
per-area 2
mentions
Caloric restriction mimetics rewire the AMPK-mTOR-ULK1 signaling nexus to restore autophagic proteostasis in the aging brain.
05-oct-2026
novelty 2
per-area 2
strengthens
Supplements for Longevity Are Everywhere, but Do They Actually Work? Experts Break Down the Science
02-oct-2026
novelty 2
per-area 1
mentions
Metformin in Elderly Patients With Type 2 Diabetes and Muscle Strength, Muscle Mass, and Physical Function: Positive or Negative Correlation?
01-oct-2026
novelty 3
per-area 3
strengthens
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
14-sep-2026
novelty 2
per-area 2
mentions
Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.
11-sep-2026
novelty 3
per-area 3
strengthens
Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.
10-sep-2026
novelty 3
per-area 3
strengthens
A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.
01-sep-2026
novelty 2
per-area 2
mentions
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
19-aug-2026
novelty 2
per-area 1
mentions
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
01-aug-2026
novelty 3
per-area 3
strengthens
Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging.
01-aug-2026
novelty 2
per-area 2
strengthens
Aging-related metabolic dysregulation in osteoporosis: mechanisms and therapeutic strategies.
27-jul-2026
novelty 2
per-area 1
mentions
p38 MAPK and MDT-15 mediate SKN-1-dependent metformin-induced protection against mitis group streptococci in Caenorhabditis elegans.
27-jul-2026
novelty 2
per-area 2
strengthens
Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing.
24-jul-2026
novelty 2
per-area 2
strengthens
Rethinking frailty as a disorder of mitochondrial adaptability, from energetic congestion to systemic vulnerability.
19-jul-2026
novelty 3
per-area 2
mentions
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
16-jul-2026
novelty 2
per-area 1
mentions
TRF2 enriched cytoplasmic chromatin drives cGAS-STAT1-mediated inflammation in senescence.
14-jul-2026
novelty 3
per-area 2
strengthens
Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism.
06-jul-2026
novelty 2
per-area 2
mentions
Effects of nutritional interventions on biomarkers of cellular senescence in humans: A systematic review.
04-jul-2026
novelty 3
per-area 2
strengthens
Metformin and cancer: active surveillance needed
04-jul-2026
novelty 2
per-area 2
weakens
From lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research.
28-jun-2026
novelty 3
per-area 2
mentions
Deep learning-based CT-derived vertebral bone mineral density and metformin therapy: a longitudinal study in the Multi-Ethnic Study of Atherosclerosis.
31-may-2026
novelty 2
per-area 2
strengthens